Product Information
PREGABALIN 225 MG CAPSULE is a generic product labeled by Cipla USA Inc., priced at $0.0635 per EA under NDC 69097068405. Its NADAC has been published 309 times since Nov 4, 2020.
FDA first approved this application on Jan 10, 2020.
Strength
225 mg/1
Manufacturer
Cipla USA Inc.NDC
69097068405
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
PREGABALINApproval Type
Generic (ANDA)
FDA Application
ANDA212280FDA Approved
1/10/2020
On Market Since
1/10/2020
Price Statistics
The NADAC for PREGABALIN 225 MG CAPSULE has been published 309 times since Nov 4, 2020, and over the history we have for it it has declined 55.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0635 per EA |
|---|---|
| All-time high | $0.1559 (Dec 16, 2020) |
| All-time low | $0.0529 (Nov 20, 2024) |
| 52-week high | $0.0690 |
| 52-week low | $0.0543 |
| Median price | $0.0844 |
| Average price | $0.0887 |
| Largest weekly change | -29.0% (Nov 20, 2024) |
| Weeks tracked | 309 |
| Tracking since | Nov 4, 2020 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the PREGABALIN capsules, CV market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Cipla USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
PREGABALIN capsules, CV market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of PREGABALIN 225 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for PREGABALIN 225 MG CAPSULE, manufactured by Cipla USA Inc., is $0.0635 per EA (NDC 69097068405), effective Sep 30, 2026.
How has the price of PREGABALIN 225 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for PREGABALIN 225 MG CAPSULE has declined 55.3%. It has been tracked across 309 weekly CMS publications since Nov 4, 2020.
What are the highest and lowest recorded NADAC prices for PREGABALIN 225 MG CAPSULE?
Since Nov 4, 2020, the NADAC for PREGABALIN 225 MG CAPSULE has ranged from a low of $0.0529 (Nov 20, 2024) to a high of $0.1559 (Dec 16, 2020), with a median of $0.0844 per EA.
Are there cheaper alternatives to PREGABALIN 225 MG CAPSULE?
No other NADAC-published product currently shares the active ingredient and strength of PREGABALIN 225 MG CAPSULE in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures PREGABALIN 225 MG CAPSULE?
PREGABALIN 225 MG CAPSULE (NDC 69097068405) is labeled by Cipla USA Inc., and CMS classifies it as a generic product.